Enanta Pharmaceuticals (ENTA) Other financing activities (2012 - 2018)

Enanta Pharmaceuticals has reported Other financing activities for 7 years, with the latest figure at -$5.5 million in Q2 2018.

• For the quarter ending Q2 2018, Other financing activities changed N/A year-over-year to -$5.5 million; the trailing twelve-month figure through Sep 2024 stood at -$5.5 million (down 68.06% YoY), and the FY2023 full-year result was $325000.0, changed N/A from the prior year.
• Other financing activities for Q2 2018 stood at -$5.5 million, down from $2.2 million in the prior quarter.
• The five-year high for Other financing activities was $2.2 million in Q1 2018, with the low at -$5.5 million in Q2 2018.
• Historically, Other financing activities has averaged -$222.22 across 5 years, with a median of -$2000.0 in 2016.
• Annual changes were most pronounced in 2015 — Other financing activities tumbled 160.0% — and 2016, when it jumped 1767.65%.
• Enanta Pharmaceuticals' Other financing activities stood at $1.9 million in 2014, then tumbled by 100.16% to -$3000.0 in 2015, then jumped by 33.33% to -$2000.0 in 2016, then tumbled by 12150.0% to -$245000.0 in 2017, then sank by 2146.53% to -$5.5 million in 2018.
• The last three Other financing activities figures came in at -$5.5 million (Q2 2018), $2.2 million (Q1 2018), and -$245000.0 (Q4 2017), per Business Quant data.